



## PORTFOLIO UPDATE – NOVEMBER 12, 2020

What a year this week has been. We are dealing with a bipolar environment of exuberance and the depths of despair punctuated by the more ritualistic and cyclical parts of society and markets. Through it all, markets have been approaching or touching all-time highs. For this reason, we have taken steps to embrace more market exposure in our model portfolios, adding modestly to US equities and more generously to US corporate credit to establish overweights to both and an underweight to cash as compared to our blended benchmarks.

A few headlines and a lot of fundamentals have brought us to this decision. In terms of headlines, what seems increasingly likely to be a Biden presidency, a slimmer Democratic majority in the House and a likely (although thinner) Republican majority retained in the Senate combine to present split governance and probably a fair amount of gridlock for two years. From a policy point of view this might not be very exciting, but it makes pricing risk a lot clearer for the markets, and that certainty seems to have buoyed performance. The second major headline came from Pfizer announcing their COVID-19 vaccine may be as much as 90% effective. That was followed shortly thereafter by news out of Eli Lilly that their monoclonal antibody therapy received a FDA emergency use authorization. Not a headline yet, but we expect with the jockeying for power this cycle coming to a conclusion there will be a turn in Washington to focusing on some form of yet-to-be-determined relief package that will bring some stimulus to the economy as we move into the holiday season.

In terms of fundamentals, and as we have written in our blogs and newsletters, economic news at least in the US has been serially positive with a powerful rebound over the last quarter. We are still behind where we were this time a year ago but markedly ahead of the depths of the pandemic crisis when the world went into lockdown. Our expectation is that equities in the US will hold their ground, with some rotation of leadership, but the general trend will be to grind higher, and high-quality corporate bonds will continue to be attractive and provide greater economic reward than Treasury securities that pay very little.

We take this step with a healthy respect for the risks still surrounding us. Europe, after a fairly quiet Summer, appears to have lost its grip on the propagation of the virus and has settled back into varying degrees of lockdown which will unquestionably drag on economic activity. Asia taken as a group has been more exacting about its pandemic controls and is still enjoying (relative) normalcy although hotspots do keep emerging. The US is making new coronavirus records every day, and parts of the community healthcare system nationally are feeling the strain, which is different than the highly concentrated outbreaks in New York and New Jersey that marked the Spring months. The US' small-L libertarian mindset means it is highly unlikely we will return to sweeping lockdowns as Europe is doing, and we are more likely to see targeted tactical moves like restaurant and bar curfews and limits on social gathering sizes but allowing business generally to continue which is supportive of jobs and economic activity. The numbers are all trending in the wrong direction, so from an investor's point of view a certain trust has to be placed that the pharmaceutical industry in partnership with academia, NGOs and governments will come through with the necessary preventatives and therapies to head the pandemic off.

Other risks include the degree to which parts of the economy have been impaired for the long term like retail, in-person dining, travel and entertainment and the drag that will apply on a return to normalcy. Thousands of businesses and millions of jobs may have been irreversibly lost, which has implications everywhere. We will be looking for efforts from municipal, state and federal government as well as private institutions to stimulate capital formation, housing stability, and job creation in the damaged parts of our communities and economy to continue the path to restoration that has brought us to this point and raised our conviction.



## DISCLOSURES

Wilde Capital Management, LLC is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and, unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.

It is important to remember that there are risks inherent in any investment and that there is no assurance that any money manager, fund, asset class, style, index or strategy will provide positive performance over time.

Diversification and strategic asset allocation do not guarantee a profit nor protect against a loss in declining markets. All investments are subject to risk, including the loss of principal.

The information contained herein is based upon the data available as of the date of this document and is subject to change at any time without notice.

Portfolios that invest in fixed income securities are subject to several general risks, including interest rate risk, credit risk, the risk of issuer default, liquidity risk and market risk. These risks can affect a security's price and yield to varying degrees, depending upon the nature of the instrument, and may occur from fluctuations in interest rates, a change to an issuer's individual situation or industry, or events in the financial markets. In general, a bond's yield is inversely related to its price. Bonds can lose their value as interest rates rise and an investor can lose principal. If sold prior to maturity, fixed income securities are subject to gains/losses based on the level of interest rates, market conditions and the credit quality of the issuer.

Foreign investments are subject to risks not ordinarily associated with domestic investments, such as currency, economic and political risks, and may follow different accounting standards than domestic investments. Investments in emerging or developing markets involve exposure to economic structures that are generally less diverse and mature, and to political systems that can be expected to have less stability than those of more developed countries. These securities may be less liquid and more volatile than investments in U.S. and longer-established non-U.S. markets.

An investment in small/mid-capitalization companies involves greater risk and price volatility than an investment in securities of larger capitalization, more established companies. Such securities may have limited marketability and the firms may have more limited product lines, markets and financial resources than larger, more established companies.

Portfolios that invest in real estate investment trusts (REITs) are subject to many of the risks associated with direct real estate ownership and, as such, may be adversely affected by declines in real estate values and general and local economic conditions. Portfolios that invest a significant portion of assets in one sector, issuer, geographical area or industry, or in related industries, may involve greater risks, including greater potential for volatility, than more diversified portfolios.

### Important Disclosures: Exchange-Traded Funds

Exchange-traded funds (ETFs) are investment vehicles that are legally classified as open-end investment companies or unit investment trusts (UITs), but differ from traditional open-end investment companies or UITs. ETF shares are bought and sold at market price (not net asset value) and are not individually redeemed from the fund. This can result in the fund trading at a premium or discount to its net asset value, which will affect an investor's value. Shares of certain ETFs have no or limited voting rights. ETFs are subject to risks similar to those of stocks.

ETFs included in portfolios may charge additional fees and expenses in addition to the advisory fee charged for the Selected Portfolio. These additional fees and expenses are disclosed in the respective fund/note prospectus. For complete details, please refer to the prospectus.

For additional information regarding advisory fees, please refer to the Fee Summary and/or Fee Detail pages (if included with this report) and the program sponsor's/each co-sponsor's Form ADV Part 2, Wrap Fee Brochure or other disclosure documents, which may be obtained through your advisor.

Certain ETFs have elected to be treated as partnerships for federal, state and local income tax purposes. Accordingly, investors in such ETFs will be taxed as a beneficial owner of an interest in a partnership. Tax information for such ETFs will be reported to investors on an IRS schedule K-1. Investors should consult with their tax advisors in determining the tax consequences of any investment, including the application of state, local or other tax laws and the possible effects of changes in federal or other tax laws.